Cardiotropic AAV gene therapy for heart failure: a phase 1 trial
Authors
Discussion
Loading...
Member takes
Implication
Phase 1 trial demonstrates improved cardiac function and safety of AAV gene therapy in heart failure, suggesting further clinical trials.
Key Points
- Improvement in cardiac function observed in patients with heart failure and reduced ejection fraction.
- Efficacy metrics showed gains in peak oxygen consumption and functional capacity from baseline evaluations.
- Evaluation included a phase 1 trial design, addressing safety and tolerability of a new gene therapy.
- Further assessments needed in clinical trials to confirm long-term benefits and efficacy outcomes.
Cite This Study
Henry et al. (2025) studied this question.